Abstract
As a paradigm for modeling gene regulatory networks, synchronous or asynchronous probabilistic Boolean networks (PBNs) provide us an effective tool to design therapeutic intervention strategies. However, most of the previous works focused on the former and only few studied the latter. This paper deals with an optimal control problem in a generalized asynchronous PBN by applying the theory on semi-Markov decision processes. Specifically, we first formulate a control model for a generalized asynchronous PBN as a first passage model for semi-Markov decision processes and then solve the corresponding optimal control problem by choosing optimal constituent Boolean networks in the asynchronous PBN such that the risk probability that the first passage time to some undesirable states associated with disease does not exceed a certain time is minimal. Numerical simulations are also provided to demonstrate the effectiveness of the proposed optimality approach.
Keywords: First passage model, generalized asynchronous probabilistic boolean network, optimal control, semi-markov decision process, gene network, therapeutic intervention policies, algorithm, dynamics, regulatory networks
Current Bioinformatics
Title: Optimal Control for Generalized Asynchronous Probabilistic Boolean Networks †
Volume: 7 Issue: 1
Author(s): Qiuli Liu, Xianping Guo and Tianshou Zhou
Affiliation:
Keywords: First passage model, generalized asynchronous probabilistic boolean network, optimal control, semi-markov decision process, gene network, therapeutic intervention policies, algorithm, dynamics, regulatory networks
Abstract: As a paradigm for modeling gene regulatory networks, synchronous or asynchronous probabilistic Boolean networks (PBNs) provide us an effective tool to design therapeutic intervention strategies. However, most of the previous works focused on the former and only few studied the latter. This paper deals with an optimal control problem in a generalized asynchronous PBN by applying the theory on semi-Markov decision processes. Specifically, we first formulate a control model for a generalized asynchronous PBN as a first passage model for semi-Markov decision processes and then solve the corresponding optimal control problem by choosing optimal constituent Boolean networks in the asynchronous PBN such that the risk probability that the first passage time to some undesirable states associated with disease does not exceed a certain time is minimal. Numerical simulations are also provided to demonstrate the effectiveness of the proposed optimality approach.
Export Options
About this article
Cite this article as:
Liu Qiuli, Guo Xianping and Zhou Tianshou, Optimal Control for Generalized Asynchronous Probabilistic Boolean Networks †, Current Bioinformatics 2012; 7 (1) . https://dx.doi.org/10.2174/157489312799304486
DOI https://dx.doi.org/10.2174/157489312799304486 |
Print ISSN 1574-8936 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-392X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stabilization of Folding Intermediate States from Alkaline Induced Unfolded State of Bovine Serum Fetuin in Trifluoroethanol and Acetonitrile
Protein & Peptide Letters Development of Vitamin D Analogs Modulating the Pocket Structure of Vitamin D Receptor
Current Topics in Medicinal Chemistry Poly-L-arginine: Enhancing Cytotoxicity and Cellular Uptake of Doxorubicin and Necrotic Cell Death
Anti-Cancer Agents in Medicinal Chemistry One-pot Synthesis of Dihydropyrano[2,3-c]chromenes via a Three-component Reaction in Aqueous Media
Combinatorial Chemistry & High Throughput Screening Synthesis of Glutamate-Zinc-Aluminium-Layered Double Hydroxide Nanobiocomposites and Cell Viability Study
Current Nanoscience Radix Astragali (Astragalus): Latest Advancements and Trends in Chemistry, Analysis, Pharmacology and Pharmacokinetics
Current Organic Chemistry A New Synthesis of Poly Heterocyclic Compounds Containing [1,2,4]triazolo and [1,2,3,4]tetrazolo Moieties and their DFT Study as Expected Anti-cancer Reagents
Current Organic Synthesis Role of ABC Transporters in Veterinary Drug Research and Parasite Resistance
Current Drug Delivery Modulation of pRb/E2F Functions in the Regulation of Cell Cycle and in Cancer
Current Cancer Drug Targets Selenium-Rich Foods: a Promising Approach to Colorectal Cancer Prevention
Current Pharmaceutical Biotechnology Risk-Benefit Perspectives in COX-2 Blockade
Current Drug Safety New Therapeutic Strategies for Coeliac Disease: Tissue Transglutaminase as a Target
Current Medicinal Chemistry Systemic Delivery of Curcumin: 21st Century Solutions for an Ancient Conundrum
Current Drug Discovery Technologies Aldo-Keto Reductase Family 1 Member B1 Inhibitors: Old Drugs with New Perspectives
Recent Patents on Anti-Cancer Drug Discovery Core Functional Sequence of C-terminal GAG-binding Domain Directs Cellular Uptake of IGFBP-3-derived Peptides
Protein & Peptide Letters Biological Activities of Eco-Friendly Synthesized Hantzsch Adducts
Medicinal Chemistry Novel Chromeno[2,3-d]pyrimidines-Design, Synthesis and Antioxidant Activity
Letters in Drug Design & Discovery Anthracyclines-Contra Cruciform Extrusion in DNA Regulating Sequences
Endocrine, Metabolic & Immune Disorders - Drug Targets Design, Synthesis, Molecular Docking, and Anticancer Evaluation of Pyrazole Linked Pyrazoline Derivatives with Carbothioamide Tail as EGFR Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Oleic Acid Protects Against Oxidative Stress Exacerbated by Cytarabine and Doxorubicin in Rat Brain
Anti-Cancer Agents in Medicinal Chemistry